Myasthenia Gravis Clinical Trials in Chapel Hill, North Carolina

3 studies are recruiting for myasthenia gravis in Chapel Hill, North Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

    This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects a…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of North Caroline at Chapel Hill-170 Manning Dr, Chapel Hill, North Carolina
    Locations
    32 in total
    Run by
    argenx

    See if you can join NCT07284420 on ClinicalTrials.gov

  2. ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

    ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life.

    Stage
    Not phased
    Ages
    18 and older
    Site
    University of North Carolina at Chapel Hill-170 Manning Dr., Chapel Hill, North Carolina
    Locations
    35 in total
    Run by
    argenx

    See if you can join NCT07294170 on ClinicalTrials.gov

  3. Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis

    This Phase 2 proof-of-concept, dose range finding study aims to evaluate the safety and efficacy of 3 dose levels of NMD670 vs placebo in adult patients with MG with antibodies against AChR or MuSK, administered twice a day (BID) for 21 days.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
    Locations
    40 in total
    Run by
    NMD Pharma A/S

    See if you can join NCT06414954 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.